03 Jun Centrose drug leads show anticancer activity
Madison, Wis. – Centrose, a Madison-based biopharmaceutical company, has announced that two of its lead drug candidates demonstrated, in animal models, strong efficacy against colorectal and non-small cell lung cancers.
The company, which is developing small molecule drug compounds based on sugar chemistry, said the tumors were shown to undergo complete remission after its drugs were administered. The drug candidates also showed considerably less toxicity than a parent drug the company has approved upon.
Other recent screening data has convinced the National Cancer Institute to proceed with canine toxicity studies, which would provide additional assessments of the Centrose compounds.
Centrose, which will present this information at the annual BIO conference this month, is using these findings to increase its business value and attract investors for a Series A financing round. The company is pursuing venture funding to finance pre-clinical studies and eventually studies in people with cancer.
Related stories
• Centrose announces drug-discovery patent
• 2007 investment metrics: Angel network tracks $120M in venture deals
• Centrose secures $1.3M in capital from Milwaukee investors
• Centrose receives $190K in federal funding to automate drug discovery platform